Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

If you know what’s causing hair loss and that it’s temporary, certain shampoos and therapies may restore fullness. Learn how ...

A study at MedUni Vienna's Department of Dermatology provides insights into the diversity of cancer-associated fibroblasts in ...

Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...

If you break your leg, ‘I’m in pain, I need fixing’. I never actually felt ill. I never felt a lump, nothing. I was picked up ...

If you break your leg, ‘I’m in pain, I need fixing’. I never actually felt ill. I never felt a lump, nothing. I was picked up ...

Inflamed acne is the opposite of a blackhead, which stays within the pore. With inflammation, acne is red, swollen, and lumpy ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Subcutaneous pembrolizumab matched IV Keytruda in key pharmacokinetic metrics in a Phase 3 NSCLC trial. Safety and efficacy ...

The mohs team at Chorley and Hospital. Lancashire Teaching Hospitals has launched a first-of-its-kind service in the region ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...